Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib/Binimetinib Master Protocol Continuation Study
2021-004395-34Phase 4Active
- Sponsor
- Pfizer
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of encorafenib and binimetinib in Nonhematologic neoplasms, sponsored by Pfizer. Started Feb 2022; status: active.
02
Drugs
encorafenibbinimetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2021-004395-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004395-34.